New 6-month results from a first-in-human trial investigating the SpyGlass drug delivery platform indicated continued reductions in intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045